Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Iris Energy Limited (IREN) Price & Performance

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

IREN trades at $34.80, showing no change in the last 24 hours. The stock faces bearish technical signals despite bullish oscillators, with key support at $34. Recent earnings misses and a negative net income margin of -99.38% highlight financial strain, though revenue grew to $501M in 2025. Analyst sentiment remains strongly positive with a consensus price target of $81.00, driven by the company's pivot to AI infrastructure and major contracts with Microsoft and NVIDIA.

The outlook is bifurcated: substantial upside exists if IREN executes its AI transition, but high valuation ratios and persistent losses pose risks. Investors should weigh the aggressive growth projections against current profitability challenges and capital intensity.